Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

2.1 Risankizumab (Skyrizi, AbbVie) 'alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs)'.

2.2 The dosage schedule is available in the summary of product characteristics for risankizumab.

2.3 The cost of a 150 mg pre-filled disposable injection of risankizumab is £3,326.09 (excluding VAT; BNF online, accessed May 2022). The company has a commercial arrangement. This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.